SRRK · Scholar Rock Holding Corp

Track SRRK — free

$43.40 -3.41 (-7.28%) At close · Oct 5

Russell 2000 member Rebalance outlook locked

Market Cap

$5.92B

121.79M

Volume · Oct 5 3.35M Avg daily vol (3M) 1.46M

Up next

Next earnings call

Nov 10, 2026 Est · unconfirmed · in 5 wks

Latest filing: 10-Q

filed Aug 6, 2026

Q2 2026 earnings call transcript

call held Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

Trailing 12 months

Net income (TTM)

−$408.59M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-5.0%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+15.9%

Year over year · more shares

Price change (1Y)

+33.0%

Trailing year

Short interest

15.9%

Latest settlement · 10.8 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 15.5 · calm Equity put/call 0.59

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −10%

below

Price vs 50-day avg −17%

below

RSI (14) 32

neutral

MACD trend Negative

52-week position 48%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −22%

trailing

6-month return −12%

trailing

YTD return −1%

this year

Relative strength −24%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $52 › 200d $48 — 50d above 200d

Institutional flow Accumulating

1 of 310 funds reported for Sep 30 · net +38 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

15.94% of float · ▲ +7.8% MoM · 10.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

310 holders — near 3-yr high, broad support

Squeeze score 74

high risk · 0–100

Fundamentals

Weak

EPS growth −33%

Y/Y

Free cash flow $-300.6M

Balance sheet $49.5M

net cash

Quant / Vol

risk profile

Very High

Volatility 59%

annualized · 1-yr

Max drawdown −32%

past year

ATR 6.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

3 · 4 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−10% Bearish

Price vs 50-day avg

−17% Bearish

RSI (14)

32 Neutral

MACD trend

Negative Bearish

52-week position

48% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $52 › 200d $48 — 50d above 200d

Institutional flow Accumulating

1 of 310 funds reported for Sep 30 · net +38 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

15.94% of float · ▲ +7.8% MoM · 10.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

310 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $28 Now $43 · 48% Range high $60

vs 200-day avg -10% vs 50-day avg -17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
SRRK Scholar Rock Holding Corp this stock	$5.92B	-1.5%	—	—	15.9%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.1%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-5.9%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+589.1%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

310

% held: 114.4%
Reported: 1 of 310
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

304

View

Short & Settlement

Short Interest Rising

Shares short

19.4M

Days to cover: 10.8d
Change: +1.4M sh

View

Short Volume

Short vol %

45%

As of: Oct 5, 2026

Short Total

View

Fails to Deliver

FTD shares

13.8K

Value: $764.4K
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

39.3%

Week of: Aug 31, 2026

Off-exch Lit

View

Financials

Revenue (FY)

Net income (FY): $-377.9M
EPS diluted: $-3.29

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 15, 2026
This year: 17

View

Proposed Sales

Value

$1.2M

Shares: 23.4K
Filed: Apr 6, 2026

View

Earnings & Events

Webcasts

Last webcast

Aug 12, 2026

View

Performance

	5D	20D	120D	MTD	YTD
SRRK	-11.7%	-21.6%	-12.4%	-10.2%	-1.5%
SPY	+1.2%	+0.6%	+11.6%	+1.6%	+13.6%
vs SPY	-12.9%	-22.2%	-24.0%	-11.8%	-15.1%

Key facts CIK 1727196 CUSIP 80706P103 13F (30d) 7 filings 6 filers Visit website Investor relations

SRRK · Scholar Rock Holding Corp

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance